VA-INTELSAT
26.6.2024 17:01:35 CEST | Business Wire | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network, signed a contract for a Starfish Otter servicing vehicle to provide life extension services to an Intelsat geostationary satellite, beginning in 2026. This landmark agreement reinforces Intelsat’s commitment to utilizing satellite servicing technologies to maximize the value its satellites can provide to customers and will mark Starfish’s first mission to provide services to a commercial satellite operator with Otter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626723807/en/
Starting in 2026, Starfish Space’s Otter will dock with a retired Intelsat satellite during a checkout campaign before maneuvering to dock with and service one of Intelsat’s operational satellites. (Courtesy: Starfish Space).
“For six decades, Intelsat has shown commitment to innovation and leveraging new technologies from throughout the industry,” said Jean-Luc Froeliger, Intelsat's Senior Vice President of Space Systems. “By engaging with emerging ventures, we create unique value for Intelsat while fostering a dynamic and competitive environment that drives advancement in space systems. Starfish is the perfect example of this kind of progress, and we look forward to utilizing the services provided by their Otter satellite to maximize the value the world’s largest geostationary satellite fleet can deliver for our customers.”
Intelsat has been a pioneer of extending satellite missions, signing its first agreement for satellite life extension in 2016, and procuring multiple additional life extension missions in recent years. The contract between Intelsat and Starfish represents a significant step for both companies, expanding the market for satellite servicing, and pushing the industry towards a new paradigm for satellite operations. With its Otter spacecraft, Starfish Space utilizes a small satellite architecture and breakthrough hardware and software technologies to provide rapid, flexible, and cost-effective on-orbit servicing missions for satellites.
Starfish will begin its first servicing mission for Intelsat in 2026. Initially, Otter will dock with and maneuver a retired Intelsat satellite in geostationary graveyard orbit. Following this initial operation, Otter will proceed to dock with and provide life extension service to an operational Intelsat satellite, using its onboard propulsion system to keep the client satellite in operational orbit for additional years of life.
“Starfish Space is delighted to be supporting Intelsat with services provided by Otter,” said Dr. Trevor Bennett, Co-Founder of Starfish Space. “They are an incredible team at the forefront of the industry and the Otter will help them deliver even more to their customers. We're also excited that this will be the first of many Otters that will make on-orbit servicing a standard part of satellite operations.”
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
About Starfish Space
Starfish Space is developing the Otter servicing vehicle to extend the lives of satellites in geostationary orbit and dispose of space debris in low-Earth orbit. Starfish has secured contracts for its first Otter missions with Intelsat and the U.S. Space Force, two of the largest global satellite operators. The company launched its Otter Pup demonstration mission in June 2023 and is now delivering on several satellite RPOD missions including its Otter mission for Intelsat. For more information, please visit starfishspace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626723807/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom